Tirzepatide: cardiovascular outcomes 2026

A large population-based cohort study published in the BMJ on 5 August 2026 found that tirzepatide reduced major adverse cardiovascular events (MACE) by 32% compared with sitagliptin in adults with type-2 diabetes and established atherosclerotic cardiovascular disease^[1]. An accompanying editorial from cardiologists at Lahey Clinic called the finding clinically meaningful but cautioned that a dedicated cardiovascular outcomes trial remains the definitive test^[2]. This article summarises both papers alongside earlier trial evidence, so readers can assess the cardiovascular story for themselves.

What the BMJ cohort study measured

Researchers Nils Krüger, Sebastian Schneeweiss, and Shirley V Wang at Harvard analysed US insurance claims from May 2022 to May 2025, enrolling 52,971 people (35,353 on tirzepatide; 17,618 on sitagliptin as the active comparator)^[1]. All participants had type-2 diabetes and documented atherosclerotic cardiovascular disease at baseline. The study used a new-user, active-comparator design to reduce confounding by indication, the methodological problem that plagues observational cardiovascular data.

At one year, MACE occurred in 2.9% of the tirzepatide group versus 4.4% on sitagliptin. The hazard ratio was 0.68 (95% CI 0.58 to 0.80), translating to a number needed to treat of 70 to prevent one MACE event^[1]. Myocardial infarction drove much of the effect (HR 0.67; 95% CI 0.52 to 0.87; NNT 130). The ischemic stroke result was weaker and did not reach statistical significance (HR 0.91; 95% CI 0.64 to 1.28).

The mortality signal that caught attention

Two secondary findings extended beyond the expected atherosclerosis mechanism. All-cause mortality was reduced (HR 0.55; 95% CI 0.42 to 0.72; NNT 122), and infection-related mortality was sharply lower (HR 0.40; 95% CI 0.26 to 0.61)^[1]. The infection finding is not explained by improved glycaemia alone. The study authors suggested that tirzepatide may have anti-inflammatory or immune-modulating effects beyond its glucose-lowering action, a hypothesis that warrants prospective investigation.

Why sitagliptin as the comparator matters

The choice of sitagliptin as the control group is both a strength and a limitation worth understanding. Sitagliptin is a DPP-4 inhibitor with a broadly neutral cardiovascular record; the TECOS trial (2015) confirmed it neither increased nor decreased MACE versus placebo. Using it as a comparator therefore gives tirzepatide a reasonable active baseline rather than a no-treatment control, which would have been unethical and logistically impossible in a diabetes population already managed on medication^[1]. The trade-off is that any hazard ratio tirzepatide earns is measured against a drug that does not itself reduce cardiovascular events. If the comparator had been an older sulfonylurea (which is associated with modestly higher cardiovascular risk) the tirzepatide benefit would have looked even larger. If the comparator had been semaglutide (which does reduce MACE), tirzepatide might not have separated. Readers should keep this framing in mind when headlines present the 32% risk reduction as a standalone claim.

How the SUMMIT trial adds to the picture

The BMJ cohort data does not stand alone. The SUMMIT trial, a randomised controlled trial published in the New England Journal of Medicine in January 2025, tested tirzepatide in 731 patients with obesity-related heart failure with preserved ejection fraction (HFpEF)^[3]. Tirzepatide reduced the composite of cardiovascular death or worsening heart failure (HR 0.62; 95% CI 0.41 to 0.95; P=0.026), and improved quality of life on the Kansas City Cardiomyopathy Questionnaire at 52 weeks. The HFpEF population is distinct from atherosclerotic cardiovascular disease, but together the two datasets point in the same direction: tirzepatide is producing cardiovascular benefit across more than one mechanism and more than one patient group.

What this evidence cannot yet settle

The BMJ study has the limitations of any observational analysis. Residual confounding is possible even with the active-comparator design; sitagliptin is not a neutral comparator (it has a broadly neutral cardiovascular track record, so any benefit from tirzepatide relative to it may understate the gap versus placebo). The follow-up is one year, too short for atherosclerosis endpoints that typically need three to five years. And the study population is US adults with insurance, which may not represent broader demographics.

The definitive answer to "does tirzepatide reduce cardiovascular events?" will come from a dedicated cardiovascular outcomes trial powered for hard endpoints. That trial has not yet been publicly announced by Eli Lilly, and the Lahey Clinic editorial authors note its absence as the key evidence gap^[2]. In that respect, tirzepatide trails semaglutide, whose LEADER trial reported a 14% relative MACE reduction versus placebo in 2016 and whose SOUL trial extended the finding to oral semaglutide in 2024. The absence of an equivalent trial means no head-to-head randomised CVOT comparison exists between the two drugs.

What a reader considering tirzepatide should take from this

The evidence base for tirzepatide and cardiovascular outcomes is strengthening. The BMJ cohort study, the SUMMIT HFpEF trial, and a July 2026 Journal of the American Heart Association analysis (HR 0.75 for MACE versus GLP-1 receptor agonists in 16,402 matched patients)^[4] all point in the same direction. None of them is a randomised CVOT powered for hard endpoints, and the Lahey editorial authors are right to call for one. Until that trial reports, the cardiovascular story for tirzepatide is consistent but incomplete.

Country-by-country prescribing status, including approval dates and indications, is on the tirzepatide regulation pages. Any decision about cardiovascular risk management and medication choice belongs with the clinician managing that risk, not with a reading of observational data.